https://scholars.lib.ntu.edu.tw/handle/123456789/484015
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | SHIH-HUNG YANG | en_US |
dc.contributor.author | YU-YUN SHAO | en_US |
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.contributor.author | SUNG-HSIN KUO | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | KUN-HUEI YEH | en_US |
dc.creator | Yeh, Kun Huei;Cheng, Ann Lii;Kuo, Sung Hsin;Lin, Chia Chi;Shao, Yu Yun;Yang, Shih Hung | - |
dc.date.accessioned | 2020-04-09T09:31:28Z | - |
dc.date.available | 2020-04-09T09:31:28Z | - |
dc.date.issued | 2018-08-01 | - |
dc.identifier.issn | 02507005 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/484015 | - |
dc.description.abstract | © 2018 International Institute of Anticancer Research. All rights reserved. Background/Aim: Radiotherapy is not routinely used in metastatic pancreatic ductal adenocarcinoma (PDAC). We conducted a phase I study to investigate concurrent chemoradiotherapy (CCRT) followed by chemotherapy. Materials and Methods: S-1 was administered at 50-70 mg/m2/day with radiotherapy in 2.5-3.6 Gy/day for 10-12 fractions. After CCRT, gemcitabine (1,000 mg/m2 on days 1 and 15) and S-1 (60-100 mg/day on days 1-7 and 15-21), were administered in a 4-week cycle. Results: After enrolling 10 patients, the study was terminated due to slow recruitment. Dose-limiting toxicities and maximum tolerated doses were not identified. Most patients experienced mild toxicities, including nausea, vomiting, and anorexia. One patient developed grade 3 infection. One patient achieved partial remission, while the remaining nine patients had stable disease, with a local disease control rate of 100% after CCRT. Conclusion: A short-course CCRT followed by chemotherapy was potentially feasible in patients with metastatic PDAC. | en_US |
dc.relation.ispartof | Anticancer Research | en_US |
dc.subject | Gemcitabine | Metastasis | Pancreatic ductal adenocarcinoma | Radiotherapy | S-1 | en_US |
dc.subject | Gemcitabine; Metastasis; Pancreatic ductal adenocarcinoma; Radiotherapy; S-1 | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | gemcitabine; gimeracil plus oteracil potassium plus tegafur; antineoplastic agent; antineoplastic antimetabolite; CA 19-9 antigen; deoxycytidine; gemcitabine; oteracil; S 1 (combination); tegafur; adult; aged; anemia; anorexia; Article; cancer combination chemotherapy; cancer control; cancer regression; chemoradiotherapy; clinical article; diarrhea; drug safety; fatigue; feasibility study; female; human; infection; liver disease; male; middle aged; multiple cycle treatment; nausea; pancreas adenocarcinoma; phase 1 clinical trial; priority journal; radiation dose fractionation; radiotherapy dosage; treatment outcome; vomiting; analogs and derivatives; blood; chemoradiotherapy; clinical trial; disease free survival; drug combination; maximum tolerated dose; pancreas carcinoma; pathology; procedures; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | - |
dc.title | A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.21873/anticanres.12790 | - |
dc.identifier.pmid | 30061252 | - |
dc.identifier.scopus | 2-s2.0-85050802783 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85050802783 | - |
dc.relation.journalvolume | 38 | en_US |
dc.relation.journalissue | 8 | en_US |
dc.relation.pageend | 4812 | en_US |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Radiation Oncology-NTUCC | - |
crisitem.author.dept | Division of Radiation Oncology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.orcid | 0000-0003-0054-887X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0002-7306-174X | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | Oncology-NTUH | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。